Clinical trial · Interventional
Metabolic Phenotypes in Melanoma
Identification of Metabolic Phenotypes Associated With Prognosis and Therapeutic Response in Patients With Melanoma
NCT05570227CI-TRIAL-00067833MetaMelrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single centre, correlative, longitudinal, biomarker study that aims to describe the metabolic features of human melanoma using mass spectrometry.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [U-13C]Glucose Infusion | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- [U-13C]Glucose Infusion
- description
- A 13.3% solution of sterile, pyrogen-free \[U-13C\]glucose in sterile water will be infused intravenously rapidly over 10 minutes to a total dose of 8 grams (bolus dose). Then the infusion will change to a rate of 4 grams/ hour. The infusion will continue until the time of tumour excision or biopsy, planned 2-3 hours.
- interventionNames
- Other: [U-13C]Glucose Infusion
- type
- NO_INTERVENTION
- label
- No [U-13C]Glucose Infusion
- description
- Blood and tissue samples to be collected for translational research studies, no other additional intervention.
Primary outcomes (2)
- measure
- Glucose Utilisation in the TCA cycle
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient has provided written informed consent 2. Male or female aged 18 years or older at written informed consent 3. Presence of a known melanoma lesion requiring surgical excision or biopsy 4. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies and receiving a stable isotope infusion (where applicable) Exclusion Criteria: Patients who meet any of the following criteria will be excluded from receiving a \[U-13C\]Glucose infusion: 1. Diabetes mellitus 2. Pregnancy or breast feeding 3. Patients unable to comply with study procedures and follow up in the opinion of the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.